The Advisory Committee on Immunization Practices (ACIP), a panel of external experts advising the Centers for Disease Control and Prevention (CDC), met to review and vote on critical vaccine recommendations for hepatitis B and COVID-19.
The committee evaluated current scientific data on vaccine safety and effectiveness, focusing on vaccine efficacy, dosing schedules, and target populations, including age groups and individuals at higher risk.
ACIP addressed the ongoing public health challenges posed by hepatitis B virus (HBV), highlighting the need to improve vaccination rates, especially among adults vulnerable to infection. Chronic HBV infection can lead to liver complications such as cirrhosis and cancer.
Regarding COVID-19, the committee discussed vaccine updates to address emerging virus variants and maintain protection against infection and transmission.
They reviewed strategies for upcoming months, emphasizing the importance of booster doses for individuals over 60, those with pre-existing conditions, and people in high-risk jobs, particularly ahead of the cold and flu season.
While ACIP’s recommendations are advisory, once approved by the CDC director, they often become official policy guiding vaccine administration nationwide. The committee members volunteer their expertise and base decisions strictly on scientific evidence, maintaining a separation from political influence.
